Skip to main content
Erschienen in: psychopraxis. neuropraxis 4/2014

01.09.2014 | Neurologie

Nicht motorische Symptome bei Morbus Parkinson

verfasst von: Dr. K. Wenzel

Erschienen in: psychopraxis. neuropraxis | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Nicht motorische Symptome bei Morbus Parkinson haben in den letzten Jahren als wesentliche Faktoren für die Lebensqualität der Patienten und deren Institutionalisierungen in späteren Krankheitsstadien zunehmend Beachtung in der Literatur gefunden. Sie treten in allen Krankheitsstadien auf. Häufig handelt es sich dabei um gastrointestinale Symptome, Blasenfunktionsstörungen, erektile Dysfunktion, orthostatische Hypotonie, Schlafstörungen, Depressionen, Demenz, Psychosen und medikamentös induzierte Verhaltensstörungen. Therapieempfehlungen werden in den Leitlinien der Österreichischen Parkinsongesellschaft und in einem rezenten Review der Movement Disorder Society nach derzeitige Datenlage und Evidenz zusammengefasst und präsentiert.
Literatur
1.
Zurück zum Zitat Antonini A, Barone P, Marconi R et al (2012) The progression of non-motor symptoms in Parkinsonʼs disease and their contribution to motor disability and quality of life. J Neurol 259(12):2621–2631PubMedCrossRef Antonini A, Barone P, Marconi R et al (2012) The progression of non-motor symptoms in Parkinsonʼs disease and their contribution to motor disability and quality of life. J Neurol 259(12):2621–2631PubMedCrossRef
2.
Zurück zum Zitat Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinsonʼs disease and depression: effect on quality of life. Mov Disord 21(8):1119–1122PubMedCrossRef Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinsonʼs disease and depression: effect on quality of life. Mov Disord 21(8):1119–1122PubMedCrossRef
3.
Zurück zum Zitat Braak H, Bohl JR, Müller CM et al (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinsonʼs disease reconsidered. Mov Disord Dec 21(12):2042–2051CrossRef Braak H, Bohl JR, Müller CM et al (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinsonʼs disease reconsidered. Mov Disord Dec 21(12):2042–2051CrossRef
4.
Zurück zum Zitat Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsonʼs disease. Mov Disord 15 24(11):1641–1649PubMedCrossRef Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsonʼs disease. Mov Disord 15 24(11):1641–1649PubMedCrossRef
5.
Zurück zum Zitat Barone P, Scarzella L, Marconi R et al (2006) Depression/Parkinson Italian study group. Pramipexole versus sertraline in the treatment of depression in Parkinsonʼs disease: a national multicenter parallel- group randomized study. J Neurol 253(5):601–607PubMedCrossRef Barone P, Scarzella L, Marconi R et al (2006) Depression/Parkinson Italian study group. Pramipexole versus sertraline in the treatment of depression in Parkinsonʼs disease: a national multicenter parallel- group randomized study. J Neurol 253(5):601–607PubMedCrossRef
6.
Zurück zum Zitat Barone P, Poewe W, Albrecht S (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinsonʼs disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 (6):573–580PubMedCrossRef Barone P, Poewe W, Albrecht S (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinsonʼs disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 (6):573–580PubMedCrossRef
7.
Zurück zum Zitat Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinsonʼs disease: diagnosis and management. Lancet Neurol 5:235–245PubMedCrossRef Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinsonʼs disease: diagnosis and management. Lancet Neurol 5:235–245PubMedCrossRef
8.
Zurück zum Zitat Chaudhuri KR, Martinez-Martin P, Odin P et al (2011) Handbook of non-motor symptoms in Parkinsonʼs disease. Springer, LondonCrossRef Chaudhuri KR, Martinez-Martin P, Odin P et al (2011) Handbook of non-motor symptoms in Parkinsonʼs disease. Springer, LondonCrossRef
9.
Zurück zum Zitat Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) An international multicentre pilot study of the the first comprehensive self-completed non motor symptoms questionnaire for Parkinsonʼs disease: the NMSQuest study. Mov Disord 21:916–923PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) An international multicentre pilot study of the the first comprehensive self-completed non motor symptoms questionnaire for Parkinsonʼs disease: the NMSQuest study. Mov Disord 21:916–923PubMedCrossRef
10.
Zurück zum Zitat Cronin-Golomb A (2013) Emergence of nonmotor symptoms as the focus of research and treatment of Parkinsonʼs disease: introduction to the special section on nonmotor dysfunctions in Parkinsonʼs disease. Behav Neurosci 127(2):135–138PubMedCrossRefPubMedCentral Cronin-Golomb A (2013) Emergence of nonmotor symptoms as the focus of research and treatment of Parkinsonʼs disease: introduction to the special section on nonmotor dysfunctions in Parkinsonʼs disease. Behav Neurosci 127(2):135–138PubMedCrossRefPubMedCentral
11.
Zurück zum Zitat Devos D, Dujardin K, Poirot I et al (2008) Comparison of desipramine and citalopram treatments for depression in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23(6):850–857PubMedCrossRef Devos D, Dujardin K, Poirot I et al (2008) Comparison of desipramine and citalopram treatments for depression in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23(6):850–857PubMedCrossRef
12.
Zurück zum Zitat Diederich NJ, Goetz CG, Stebbins GT (2005) Repeated visual hallucinations inParkinsonʼs disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 20(2):130–140PubMedCrossRef Diederich NJ, Goetz CG, Stebbins GT (2005) Repeated visual hallucinations inParkinsonʼs disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 20(2):130–140PubMedCrossRef
13.
Zurück zum Zitat Dubois B, Tolosa E, Katzenschlager R et al (2012) Donepezil in Parkinsonʼs disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 27(10):1230–1238PubMedCrossRef Dubois B, Tolosa E, Katzenschlager R et al (2012) Donepezil in Parkinsonʼs disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 27(10):1230–1238PubMedCrossRef
14.
Zurück zum Zitat Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinsonʼs disease. N Engl J Med 351(24):2509–2518PubMedCrossRef Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinsonʼs disease. N Engl J Med 351(24):2509–2518PubMedCrossRef
15.
Zurück zum Zitat Hussain IF, Brady CM, Swinn MJ et al (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinsonʼs disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71(3):371–374PubMedCrossRefPubMedCentral Hussain IF, Brady CM, Swinn MJ et al (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinsonʼs disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71(3):371–374PubMedCrossRefPubMedCentral
16.
Zurück zum Zitat Lagalla G, Millevolte M, Capecci M et al (2006) Botulinumtoxin type A for drooling in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21(5):704–707PubMedCrossRef Lagalla G, Millevolte M, Capecci M et al (2006) Botulinumtoxin type A for drooling in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21(5):704–707PubMedCrossRef
17.
Zurück zum Zitat Litvinenko IV, Odinak MM, Mogil’naya VI et al (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinsonʼs disease (an open controlled trial). Neurosci Behav Physiol 38(9):937–945PubMedCrossRef Litvinenko IV, Odinak MM, Mogil’naya VI et al (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinsonʼs disease (an open controlled trial). Neurosci Behav Physiol 38(9):937–945PubMedCrossRef
18.
Zurück zum Zitat Maricle RA, Nutt JG, Valentine RJ et al (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinsonʼs disease: a double-blind, placebo-controlled study. Neurology 45(9):1757–1760PubMedCrossRef Maricle RA, Nutt JG, Valentine RJ et al (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinsonʼs disease: a double-blind, placebo-controlled study. Neurology 45(9):1757–1760PubMedCrossRef
19.
Zurück zum Zitat Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinsonʼs disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11) 1623–1629PubMedCrossRef Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinsonʼs disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11) 1623–1629PubMedCrossRef
20.
Zurück zum Zitat Menza M, Dobkin RD, Marin H et al (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886–892PubMedCrossRefPubMedCentral Menza M, Dobkin RD, Marin H et al (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886–892PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinsonʼs disease. Neurology 62(1):37–40PubMedCrossRef Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinsonʼs disease. Neurology 62(1):37–40PubMedCrossRef
22.
Zurück zum Zitat Ondo WG, Levy JK, Vuong KD, Hunter C et al (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17(5):1031–1035PubMedCrossRef Ondo WG, Levy JK, Vuong KD, Hunter C et al (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17(5):1031–1035PubMedCrossRef
23.
Zurück zum Zitat Pollak P, Tison F, Rascol O et al (2004) Clozapine in drug induced psychosis in Parkinsonʼs disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695PubMedCrossRefPubMedCentral Pollak P, Tison F, Rascol O et al (2004) Clozapine in drug induced psychosis in Parkinsonʼs disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695PubMedCrossRefPubMedCentral
24.
Zurück zum Zitat Rabinak, CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinsonʼs disease. Arch of Neurol 67(1) 58–63CrossRef Rabinak, CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinsonʼs disease. Arch of Neurol 67(1) 58–63CrossRef
25.
Zurück zum Zitat Rektorová I, Rektor I, Bares M et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinsonʼs disease: a national multicentre prospective randomized study. Eur J Neurol 10(4):399–406PubMedCrossRef Rektorová I, Rektor I, Bares M et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinsonʼs disease: a national multicentre prospective randomized study. Eur J Neurol 10(4):399–406PubMedCrossRef
26.
Zurück zum Zitat Schoffer KL, Henderson RD, O’Maley K et al (2007) Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinsonʼs disease. Mov Disord 22(11):1543–1549PubMedCrossRef Schoffer KL, Henderson RD, O’Maley K et al (2007) Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinsonʼs disease. Mov Disord 22(11):1543–1549PubMedCrossRef
27.
Zurück zum Zitat Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinsonʼs disease? J Neurol Neurosurg Psychiatry 69:308–312PubMedCrossRefPubMedCentral Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinsonʼs disease? J Neurol Neurosurg Psychiatry 69:308–312PubMedCrossRefPubMedCentral
28.
Zurück zum Zitat Seppi K, Auff E, Haubenberger D et al (2013) Leitlinien zur Behandlung der Parkinson-Krankheit. Teil 2: Nichtmotorische Symptome. Neurologisch Suppl 2:1–21 Seppi K, Auff E, Haubenberger D et al (2013) Leitlinien zur Behandlung der Parkinson-Krankheit. Teil 2: Nichtmotorische Symptome. Neurologisch Suppl 2:1–21
29.
Zurück zum Zitat Seppi K, Weintraub D, Coelho M et al (2011). The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinsonʼs disease. Mov Disord. Suppl 3:42–80CrossRef Seppi K, Weintraub D, Coelho M et al (2011). The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinsonʼs disease. Mov Disord. Suppl 3:42–80CrossRef
30.
Zurück zum Zitat Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800–809PubMedCrossRef Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800–809PubMedCrossRef
31.
Zurück zum Zitat Thomas A, Bonanni L, Gambi F et al (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404PubMedCrossRef Thomas A, Bonanni L, Gambi F et al (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404PubMedCrossRef
32.
Zurück zum Zitat Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRefPubMedCentral Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRefPubMedCentral
33.
Zurück zum Zitat Witjas T, Kaphan E, Azulay JP et al (2002) Nonmotor fluctuations in Parkinsonʼs disease. Frequent and disabling. Neurology 59:408–413PubMedCrossRef Witjas T, Kaphan E, Azulay JP et al (2002) Nonmotor fluctuations in Parkinsonʼs disease. Frequent and disabling. Neurology 59:408–413PubMedCrossRef
34.
Zurück zum Zitat Zangaglia R, Martignoni E, Glorioso M et al (2007) Macrogol for the treatment of constipation in Parkinsonʼs disease. A randomized placebo-controlled study. Mov Disord 22(9):1239–1244PubMedCrossRef Zangaglia R, Martignoni E, Glorioso M et al (2007) Macrogol for the treatment of constipation in Parkinsonʼs disease. A randomized placebo-controlled study. Mov Disord 22(9):1239–1244PubMedCrossRef
Metadaten
Titel
Nicht motorische Symptome bei Morbus Parkinson
verfasst von
Dr. K. Wenzel
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 4/2014
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-014-0192-3

Weitere Artikel der Ausgabe 4/2014

psychopraxis. neuropraxis 4/2014 Zur Ausgabe

aktuell

Aktuell